A prospective multicenter cohort study of cutaneous melanoma: clinical staging and potential associations with HIF-1α and VEGF expressions
A prospective multicenter cohort study of cutaneous melanoma: clinical staging and potential associations with HIF-1α and VEGF expressions
复制标题
DOI：
10.1097/cmr.0000000000000393
复制
发表时间：
2017-12-01
影响因子：
2.2
通讯作者：
Gozal, David
中科院分区：
文献类型：
--
作者：
Angel Martinez-Garcia, Miguel;Riveiro-Falkenbach, Erica;Gozal, David
黑色素瘤是一种高度流行的癌症，与大量死亡率相关。虽然临床分期程序可以作为相对可靠的预后指标，我们的目的是确定是否评估缺氧诱导因子-1 α（HIF-1 α）或血管内皮生长因子（VEGF）的丰度在切除后的黑色素瘤肿瘤组织可以更准确地确定肿瘤的侵袭性。我们进行了一项多中心前瞻性研究，在该研究中，我们系统地评估了376例诊断为黑色素瘤的连续患者，并对肿瘤活检组织中的HIF-1 α和VEGF免疫反应性进行了组织化学评估。多变量分析显示，高HIF-1 α表达，而不是高VEGF，与肿瘤侵袭性增加显著和独立相关，如来自几个公认的侵袭性标准。本研究的局限性在于，这是一项描述性前瞻性研究，缺乏事后验证臂。因此，在黑色素瘤肿瘤中，阳性标记的HIF-1 α细胞数量增加可能潜在地作为肿瘤表型和预后的指标，从而指导治疗。版权所有（C）2017威科医疗集团All rights reserved.
Melanoma is a highly prevalent cancer that is associated with substantial mortality. Although clinical staging procedures can serve as relatively robust prognostic indicators, we aimed to determine whether assessments of the abundance of hypoxia inducible factor-1 alpha (HIF-1 alpha) or vascular endothelial growth factor (VEGF) in postexcisional melanoma tumor tissues may enable more accurate determination of tumor aggressiveness. We carried out a multicenter prospective study, in which we systematically evaluated 376 consecutive patients diagnosed with melanoma, and performed histochemical assessments for both HIF-1 alpha and VEGF immunoreactivity in the tumor biopsies. Multivariate analyses showed that higher HIF-1 alpha expression, but not high VEGF, were associated significantly and independently with increased tumor aggressiveness as derived from several well-established aggressiveness criteria. A limitation of this study was that this was a descriptive prospective study lacking a post-hoc verification arm. Thus, the presence of increased numbers of positively labeled HIF-1 alpha cells in melanoma tumors may potentially serve as an indicator of tumor phenotype and prognosis, and accordingly guide therapy. Copyright (C) 2017 Wolters Kluwer Health, Inc. All rights reserved.